Author(s): Horváth B, Janse IC, Sibbald GR
Hidradenitis suppurativa (HS) is a chronic, relapsing, and painful inflammatory disease. HS patients’ quality of life is severely impaired, and this impairment correlates strongly with their pain. Pain in HS can be acute or chronic and has both inflammatory and noninflammatory origins. The purpose of this review is to provide a summary of the existing literature regarding pain management in patients with HS. While there are no formal studies investigating pain management in HS, existing recommendations are based on general pain guidelines and expert opinion. Documentation of pain requires an assessment of the severity and timing of the pain. Although anti-inflammatory drugs and surgery for HS can alleviate pain, adjunctive pain medications are typically necessary. Topical analgesics, oral acetaminophen, and oral nonsteroidal anti-inflammatory drugs are considered first-line agents for the treatment of pain in patients with HS. If pain management is ineffective with those agents, oral opiates can be considered. In addition, anticonvulsants and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors possess neuropathic pain-relieving properties that offer not only control of HS-associated pain but beneficial effects on itch and depression. There is clearly a need for additional studies on pain management in patients with HS.
Dermatology Journal and/or Publisher
Journal Name: Journal of the American Academy of Dermatology
Journal Abbreviation: J. Am. Acad. Dermatol.
Journal Date Published: 2015-10-16
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/26470616
Lasted Revision: 2015-10-16
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).